在2型糖尿病中减少治疗惯性
Mark L Stroud1, Asif N Malik2, Shahid Ahmad3
1MBBS, MPH+TM, FRACGP, DipRACOG, Consultant Family Medicine, Mesaimeer Health Center, Primary Health Care Corporation, Qatar.
Australian journal of general practice
|September 3, 2024
概括
治疗惯性,即未能加强糖尿病治疗,影响了三分之一的咨询. 解决这个系统问题是改善患者结果和降低2型糖尿病管理中的心血管风险的关键.
科学领域:
- 内分泌学 在内分泌学.
- 心血管医学 心血管医学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 治疗惯性被定义为未能启动或升级治疗以实现治疗目标.
- 这种现象在约三分之一的2型糖尿病管理咨询中观察到.
- 它代表了医疗保健的系统性问题,而不是个体医生或患者的错误.
研究的目的:
- 突出降低2型糖尿病治疗惯性的重要性.
- 强调全面的心血管风险降低战略的重要性.
主要方法:
- 讨论各种方法来克服治疗惯性.
- 介绍治疗到目标的方法.
- 解释STABLE (戒烟,目标器官参与,HbA1c,血压,脂质概况,能量平衡) 的缩写和实际实施策略.
主要成果:
- 有证据表明,治疗惯性是糖尿病护理的重要障碍.
- 可以实施系统方法来解决和减少这种惯性.
- 治疗到目标的方法和STABLE框架提供了实际指导.
结论:
- 减少治疗惯性对于优化2型糖尿病管理至关重要.
- 专注于心血管风险降低以及血糖控制是必不可少的.
- 实施结构化方法可以改善治疗强化和患者的治疗结果.
相关概念视频
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Insulin: Dosing Regimen and Adverse Effects
160
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
160
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Carbohydrate Metabolism
10.9K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.9K
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306


